NCT03687242View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 6, 2018

Primary Completion Date

July 8, 2019

Study Completion Date

August 9, 2019

Conditions
Congenital Adrenal HyperplasiaCAH - Congenital Adrenal HyperplasiaCAH - 21-Hydroxylase Deficiency
Interventions
DRUG

SPR001

Open label SPR001

Trial Locations (8)

19104

Spruce Biosciences Clinical Site, Philadelphia

30046

Spruce Biosciences Clinical Site, Atlanta

46202

Spruce Biosciences Clinical Site, Indianapolis

48109

Spruce Biosciences Clinical Site, Ann Arbor

55414

Spruce Biosciences Clinical Site, Minneapolis

89148

Spruce Biosciences Clinical Site, Las Vegas

92123

Spruce Biosciences Clinical Site, San Diego

92868

Spruce Biosciences Clinical Site, Orange

Sponsors

Lead Sponsor

Spruce Biosciences
All Listed Sponsors
lead

Spruce Biosciences

INDUSTRY

NCT03687242 - Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia | Biotech Hunter | Biotech Hunter